The Vaccine Product, Price and Procurement (V3P) Project
The Project working team consists of WHO and Partners staff as well as expert consultants.
For more information, please contact us via email.
Launched in September 2011, the V3P Project is a three year initiative led by WHO and funded by the Bill and Melinda Gates Foundation.
The V3P project has been designed to respond to the needs identified by the global health community. Some of the Middle Income Countries (MIC) have not achieved the sustainable introduction of new and priority vaccines at the same rates as the High Income Countries (HIC) and donor funded Low Income Countries (LIC).
A subset of the MIC are the GAVI Graduating countries (see link below). These countries may run the risk of being unable to sustain all the gains achieved in the introduction of new vaccines during their GAVI eligibility period. The lack of reliable, accurate and neutral vaccine product, price and procurement information and data has been identified as a key obstacle for both GAVI Graduating and MIC. Such information and data are essential to making informed decisions regarding the forecasting, budgeting, and sustainable financing of new and priority vaccines.
Currently there is no comprehensive information source available for vaccine prices. Some prices are published by individual countries and by large pooled procurement groups such as the UNICEF Supply Division and the PAHO Revolving Fund. When using such information, however, it requires a certain level of understanding of the procurement systems providing the information, the ability to identify which products are eligible for comparison and how to conduct the proper interpretation and analysis of data.
The goal of the V3P is to identify, develop and establish the most appropriate and comprehensive method(s), mechanism(s) and/or tools to provide countries with accurate, reliable and useful data on vaccine product, price and procurement.
A publicly available and sustainable information mechanism providing reliable, accurate and neutral information and data on vaccine product, price and procurement, allowing for increased price transparency and more informed decision making in the vaccine implementation and procurement processes.
Improved knowledge and utilization of information allowing for the increased, systematic and sustainable implementation of new and priority vaccines for MIC and GAVI graduating countries.
Practical uses of V3P information
- Increasing vaccine market knowledge;
- Planning future vaccine investment;
- Identifying opportunities for improvements of procurement systems;
- Conducting cost-benefit and cost-utility analyses;
- Advocating for resource mobilization;
- Short- and long-term planning and budgeting of immunization programmes;
- Benefiting from and contributing to global and regional initiatives.
Decision makers and managers of immunization programmes in countries, and those providing advice, data and evidence for informed decisions on sustainable vaccine implementation in MIC and GAVI graduating countries.
Members of the V3P Steering Committee include representatives from:
- The Bill and Melinda Gates Foundation
- Center for Global Development
- GAVI Secretariat
- The Global Fund
- PAHO Revolving Fund
- Results for Development
- SIVAC Initiative/Agence de Médecine Préventive
- UNICEF Supply Division
- WHO HQ and Regional Offices